<html><head>
	<title>navb20221221_s8.htm</title>

	<!-- Generated by ThunderDome Portal - 12/22/2022 3:37:45 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>As filed with the Securities and Exchange Commission on</b>&nbsp;<b>December 22, 2022</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Registration No.</b>&nbsp;<b>333-[_____]</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&nbsp;</p>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>UNITED STATES</b><br>
<b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>&#8203;FORM S-8</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>REGISTRATION STATEMENT</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNDER</b><br>
<b>THE SECURITIES ACT OF 1933</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>NAVIDEA BIOPHARMACEUTICALS, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:0.2%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p>
			</td>
			<td style="vertical-align:top;width:31.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Delaware</b>&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:31.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#8203;&#8203;2835 </b></p>
			</td>
			<td style="vertical-align:top;width:31.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>31-1080091</b></p>
			</td>
			<td style="vertical-align:top;width:0.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:0.2%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p>
			</td>
			<td style="vertical-align:top;width:31.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or Other Jurisdiction of<br>
			Incorporation or Organization)</p>
			</td>
			<td style="vertical-align:top;width:31.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Primary Standard Industrial</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Classification Code Number)</p>
			</td>
			<td style="vertical-align:top;width:31.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Identification Number)</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8203;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>4995 Bradenton Avenue, Suite 240</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Dublin, Ohio 43017</b><br>
<b>(614) 793-7500</b><br>
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Michael S. Rosol, Ph.D.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Chief Medical Officer</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Navidea Biopharmaceuticals, Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>4995 Bradenton Avenue, Suite 240</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Dublin, Ohio 43017</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(614) 793-7500</b><br>
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Copies to:</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>William M. Mower, Esq.</b><br>
<b>Maslon LLP</b><br>
<b>90 South 7</b><b><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></b><b> Street, Suite 3300</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Minneapolis, MN 55402</b>&#8203;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:25.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Large accelerated filer &#9744;</p>
			</td>
			<td style="vertical-align:top;width:20.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accelerated filer &#9744;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:25.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Non-accelerated filer&nbsp;&nbsp;&#9746;</p>
			</td>
			<td style="vertical-align:top;width:20.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Smaller reporting company &#9746;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:25.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Emerging growth company &#9744;</p>
			</td>
			<td style="vertical-align:top;width:20.8%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div contenteditable="false" data-applyto="p" data-auto-pgnum="start" data-displaynum="2" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="2" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>REGISTRATION OF ADDITIONAL SECURITIES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This Registration Statement is filed by Navidea Biopharmaceuticals, Inc. (the &#8220;Company&#8221;) to register an additional 6,000,000 shares of Common Stock issuable pursuant to the 2014 Stock Incentive Plan, as amended and restated as of December 8, 2022 (the &#8220;2014 Plan&#8221;). These securities are being registered in addition to the securities previously registered for issuance under the 2014 Plan on the Company&#8217;s registration statements on Form S-8 (File Nos. 333-198716, 333-228960 and 333-250078) filed with the U.S. Securities and Exchange Commission (the&nbsp;&#8220;SEC&#8221;) on <a href="http://www.sec.gov/Archives/edgar/data/810509/000114420414055662/v389004_s-8.htm" style="-sec-extract:exhibit;"><u>September 12, 2014</u></a>, <a href="http://www.sec.gov/Archives/edgar/data/810509/000143774918022458/navb20181219_s8.htm" style="-sec-extract:exhibit;"><u>December 21, 2018</u></a> and <a href="http://www.sec.gov/Archives/edgar/data/810509/000143774920023842/navb20201112_s8.htm" style="-sec-extract:exhibit;"><u>November 13, 2020</u></a>, respectively (the &#8220;2014 Registration Statement&#8221;). In accordance with General Instruction E to Form S-8, the contents of the 2014 Registration Statement (including all attachments and exhibits thereto), are incorporated herein by reference, except to the extent supplemented, amended or superseded by the information set forth herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">2</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART II</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 3.</b>&nbsp;<b>Incorporation of Documents by Reference</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company incorporates by reference into this Registration Statement the following documents that the Company has previously filed with the SEC:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774922007390/navb20211231_10k.htm" style="-sec-extract:exhibit;"><u>March 28, 2022</u></a>;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022, June 30, 2022 and September 30, 2022, filed with the SEC on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774922012668/navb20220331_10q.htm" style="-sec-extract:exhibit;"><u>May 16, 2022</u></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774922020558/navb20220630_10q.htm" style="-sec-extract:exhibit;"><u>August 15, 2022</u></a>, and <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774922027321/navb20220930_10q.htm" style="-sec-extract:exhibit;"><u>November 14, 2022</u></a>, respectively;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Current Reports on Form 8-K and all amendments thereto on Form 8-K/A, filed with the SEC on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774922002377/navb20220203_8k.htm" style="-sec-extract:exhibit;"><u>February 3, 2022</u></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774922008494/navb20220407_8k.htm" style="-sec-extract:exhibit;"><u>April 7, 2022</u></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774922008751/navb20220411_8k.htm" style="-sec-extract:exhibit;"><u>April 12, 2022</u></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774922009286/navb20220419_8k.htm" style="-sec-extract:exhibit;"><u>April 20, 2022</u></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774922021819/navb20220902_8k.htm" style="-sec-extract:exhibit;"><u>September 2, 2022</u></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774922022540/navb20220915_8k.htm" style="-sec-extract:exhibit;"><u>September 15, 2022</u></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774922023281/navb20220929_8k.htm" style="-sec-extract:exhibit;"><u>September 30, 2022</u></a>&nbsp;and <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/810509/000143774922028918/navb20221212_8k.htm" style="-sec-extract:exhibit;"><u>December 12, 2022</u></a>;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Definitive Proxy Statement filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/810509/000143774922024633/navb20221024b_def14a.htm" style="-sec-extract:exhibit;"><u>October 24, 2022</u></a>; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The description of the Company&#8217;s Common Stock which is contained in the Company&#8217;s Form 8-A filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/810509/000114420411006496/v210364_8a-12b.htm" style="-sec-extract:exhibit;"><u>February&nbsp;8, 2011</u></a>, including all amendments and reports filed for the purpose of updating such description.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. Any statement incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">3</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 8.</b>&nbsp;<b>Exhibits</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Exhibit Number</b></p>
			</td>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:34pt;"><b>Description</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:38.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">&nbsp;&nbsp;5.1</p>
			</td>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_458445.htm" style="-sec-extract:exhibit;">Opinion of Maslon LLP regarding legality.</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:38.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">10.1</p>
			</td>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_458446.htm" style="-sec-extract:exhibit;">Navidea Biopharmaceuticals, Inc. 2014 Stock Incentive Plan (as amended and restated as of December 8, 2022).</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:38.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">23.1</p>
			</td>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_458445.htm" style="-sec-extract:exhibit;">Consent of Maslon LLP (included in Exhibit 5.1).</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:38.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">23.2</p>
			</td>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_458468.htm" style="-sec-extract:exhibit;">Consent of Marcum LLP.</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:38.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">24.1</p>
			</td>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#poa" style="-sec-extract:exhibit;">Powers of Attorney (included on signature page hereto).</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:38.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">107</p>
			</td>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_458447.htm" style="-sec-extract:exhibit;">Calculation of Filing Fee Table.</a></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">4</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Signatures</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements of filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dublin, State of Ohio, on December 22, 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:23.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NAVIDEA BIOPHARMACEUTICALS, INC.</b></p>
			</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:23.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:21.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:23.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:21.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:23.1%;">&nbsp;</td>
			<td style="vertical-align: top; width: 21.4%; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>/s/ Michael S. Rosol</i></p>
			</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:23.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Michael S. Rosol, Ph.D.</p>
			</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:23.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:21.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Medical Officer (Principal Executive Officer)</p>
			</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="poa" name="poa" title="poa"></a>POWER OF ATTORNEY</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Each person whose signature appears below constitutes and appoints Michael S. Rosol, Ph.D. as his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto and other documents in connection therewith) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Signature</b></p>
			</td>
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title</b></p>
			</td>
			<td style="vertical-align:top;width:12.5%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;"><b>Date</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Michael S. Rosol</i></p>
			</td>
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Chief Medical Officer</p>
			</td>
			<td style="vertical-align:top;width:12.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">December 22, 2022</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Michael S. Rosol, Ph.D.</p>
			</td>
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">(Principal Executive Officer)</p>
			</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Erika L. Eves</i></p>
			</td>
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Vice President, Finance &amp; Administration</p>
			</td>
			<td style="vertical-align:top;width:12.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">December 22, 2022</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Erika L. Eves</p>
			</td>
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">(Principal Financial Officer and Principal</p>
			</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Accounting Officer)</p>
			</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Alexander L. Cappello</i></p>
			</td>
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Chair of the Board of Directors</p>
			</td>
			<td style="vertical-align:top;width:12.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">December 22, 2022</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Alexander L. Cappello</p>
			</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ John K. Scott, Jr.</i></p>
			</td>
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Vice Chair of the Board of Directors</p>
			</td>
			<td style="vertical-align:top;width:12.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">December 22, 2022</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">John K. Scott, Jr.</p>
			</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Amit Bhalla</i></p>
			</td>
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:12.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">December 22, 2022</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Amit Bhalla</p>
			</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Joshua M. Wilson</i></p>
			</td>
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:12.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">December 22, 2022</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Joshua M. Wilson</p>
			</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Malcolm G. Witter</i></p>
			</td>
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:12.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">December 22, 2022</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Malcolm G. Witter</p>
			</td>
			<td style="vertical-align:top;width:19.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:12.5%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>
</div>


</body></html>
[{"type": "S-8", "sequence": "1", "filename": "navb20221221_s8.htm", "description": "FORM S-8", "secsgml_size_bytes": 40543}]
{"company-data": {"conformed-name": "NAVIDEA BIOPHARMACEUTICALS, INC.", "cik": "0000810509", "assigned-sic": "2835", "irs-number": "311080091", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-268956", "film-number": "221482205"}, "business-address": {"street1": "4995 BRADENTON AVENUE", "street2": "SUITE 240", "city": "DUBLIN", "state": "OH", "zip": "43017", "phone": "6147937500"}, "mail-address": {"street1": "4995 BRADENTON AVENUE", "street2": "SUITE 240", "city": "DUBLIN", "state": "OH", "zip": "43017"}, "former-company": {"former-conformed-name": "NEOPROBE CORP", "date-changed": "19940714"}}
navb20221221_s8.htm
As filed with the Securities and Exchange Commission on
December 22, 2022
Registration No.
333-[_____]
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
​FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
NAVIDEA BIOPHARMACEUTICALS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
​
Delaware
​​2835
31-1080091
​
​
(State or Other Jurisdiction of
Incorporation or Organization)
(Primary Standard Industrial
Classification Code Number)
(I.R.S. Employer
Identification Number)
​
4995 Bradenton Avenue, Suite 240
Dublin, Ohio 43017
(614) 793-7500
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)
Michael S. Rosol, Ph.D.
Chief Medical Officer
Navidea Biopharmaceuticals, Inc.
4995 Bradenton Avenue, Suite 240
Dublin, Ohio 43017
(614) 793-7500
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)
Copies to:
William M. Mower, Esq.
Maslon LLP
90 South 7
th
Street, Suite 3300
Minneapolis, MN 55402
​
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer  ☒
Smaller reporting company ☒
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
REGISTRATION OF ADDITIONAL SECURITIES
This Registration Statement is filed by Navidea Biopharmaceuticals, Inc. (the "Company") to register an additional 6,000,000 shares of Common Stock issuable pursuant to the 2014 Stock Incentive Plan, as amended and restated as of December 8, 2022 (the "2014 Plan"). These securities are being registered in addition to the securities previously registered for issuance under the 2014 Plan on the Company's registration statements on Form S-8 (File Nos. 333-198716, 333-228960 and 333-250078) filed with the U.S. Securities and Exchange Commission (the "SEC") on
September 12, 2014
,
December 21, 2018
and
November 13, 2020
, respectively (the "2014 Registration Statement"). In accordance with General Instruction E to Form S-8, the contents of the 2014 Registration Statement (including all attachments and exhibits thereto), are incorporated herein by reference, except to the extent supplemented, amended or superseded by the information set forth herein.
2
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3.
Incorporation of Documents by Reference
The Company incorporates by reference into this Registration Statement the following documents that the Company has previously filed with the SEC:
●
Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on
March 28, 2022
;
●
Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022, June 30, 2022 and September 30, 2022, filed with the SEC on
May 16, 2022
,
August 15, 2022
, and
November 14, 2022
, respectively;
●
Current Reports on Form 8-K and all amendments thereto on Form 8-K/A, filed with the SEC on
February 3, 2022
,
April 7, 2022
,
April 12, 2022
,
April 20, 2022
,
September 2, 2022
,
September 15, 2022
,
September 30, 2022
and
December 12, 2022
;
●
Definitive Proxy Statement filed with the SEC on
October 24, 2022
; and
●
The description of the Company's Common Stock which is contained in the Company's Form 8-A filed with the SEC on
February 8, 2011
, including all amendments and reports filed for the purpose of updating such description.
All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. Any statement incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
3
Item 8.
Exhibits
Exhibit Number
Description
5.1
Opinion of Maslon LLP regarding legality.
10.1
Navidea Biopharmaceuticals, Inc. 2014 Stock Incentive Plan (as amended and restated as of December 8, 2022).
23.1
Consent of Maslon LLP (included in Exhibit 5.1).
23.2
Consent of Marcum LLP.
24.1
Powers of Attorney (included on signature page hereto).
107
Calculation of Filing Fee Table.
4
Signatures
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements of filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dublin, State of Ohio, on December 22, 2022.
NAVIDEA BIOPHARMACEUTICALS, INC.
/s/ Michael S. Rosol
Michael S. Rosol, Ph.D.
Chief Medical Officer (Principal Executive Officer)
POWER OF ATTORNEY
Each person whose signature appears below constitutes and appoints Michael S. Rosol, Ph.D. as his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto and other documents in connection therewith) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:
Signature
Title
Date
/s/ Michael S. Rosol
Chief Medical Officer
December 22, 2022
Michael S. Rosol, Ph.D.
(Principal Executive Officer)
/s/ Erika L. Eves
Vice President, Finance & Administration
December 22, 2022
Erika L. Eves
(Principal Financial Officer and Principal
Accounting Officer)
/s/ Alexander L. Cappello
Chair of the Board of Directors
December 22, 2022
Alexander L. Cappello
/s/ John K. Scott, Jr.
Vice Chair of the Board of Directors
December 22, 2022
John K. Scott, Jr.
/s/ Amit Bhalla
Director
December 22, 2022
Amit Bhalla
/s/ Joshua M. Wilson
Director
December 22, 2022
Joshua M. Wilson
/s/ Malcolm G. Witter
Director
December 22, 2022
Malcolm G. Witter
5